Roxadustat for anemia in myelodysplastic syndromes
Treatments studied
Part of Blood & lymphatic clinical trials.
This trial tests a pill called roxadustat to help treat anemia in people with myelodysplastic syndromes (MDS). It might reduce the need for blood transfusions and improve energy levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with myelodysplastic syndromes (MDS).
- Your MDS is considered low, very low, or intermediate risk.
- You need at least 4 blood transfusions every 2 months.
- You have tried or cannot use ESAs, which are medicines that help your body make red blood cells.
- You are in reasonably good health and able to care for yourself (ECOG performance status 0, 1, or 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called elritercept for people with myelodysplastic syndromes (MDS) who have low blood counts and need regular blood transfusions. The drug aims to boost red blood cell production and reduce or eliminate the need for transfusions, which can improve energy and quality of life.
This trial tests an investigational drug, TAK-226, for people with lower-risk myelodysplastic syndromes (MDS) who have anemia. The study aims to see if the drug can help improve blood counts and reduce the need for red blood cell transfusions.
This trial is testing a new medicine called HS-20106 to see if it can improve anemia (low red blood cells) for people with certain types of MDS. If it works, it might reduce the need for blood transfusions.
This trial tests elritercept, a medicine meant to improve anemia (low blood count) in adults with certain lower-risk bone marrow disorders called MDS. If you qualify, the study may help reduce the need for blood transfusions or improve anemia symptoms.
This trial tests a new oral medication (iadademstat) combined with a standard therapy called a hypomethylating agent for people with higher-risk myelodysplastic syndromes (MDS) or related blood cancers. The goal is to see if the combination is safe and effective.
This study looks at whether a drug called roxadustat helps people who have heart failure, anemia, and moderate-to-severe chronic kidney disease. The trial focuses on people who have already been taking roxadustat for more than a year.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.